Starbucks
SBUX
$95.51
-1.04%
Starbucks Corp is the world's largest and most recognizable coffee brand, operating a global network of nearly 41,000 company-operated and licensed cafes across over 80 countries. The company is a dominant market leader in the premium coffeehouse segment, distinguished by its powerful brand, extensive global footprint, and a business model that blends direct retail with licensing and product sales. The current investor narrative is sharply focused on the company's ongoing turnaround strategy under CEO Brian Niccol, with recent news highlighting encouraging early signs of sales and profit growth, corporate layoffs to streamline costs, and a significant stock rally as the market assesses the traction of these operational improvements.…
SBUX
Starbucks
$95.51
Related headlines
Investment Opinion: Should I buy SBUX Today?
Rating & Thesis: Hold. SBUX is a high-risk, high-reward turnaround story where the potential for operational recovery is already substantially priced in, demanding flawless execution to justify the current valuation. The mixed analyst sentiment, with recent downgrades alongside bullish calls, underscores this precarious balance.
Supporting Evidence: The stock trades at a lofty 52.58x trailing PE, though the forward PE of 32.74x prices in the expected EPS recovery to $5.08. Revenue growth remains positive at 5.43% YoY but is inconsistent quarter-to-quarter. Profitability is the critical weak point, with net margin collapsing to 2.96%. Positively, robust TTM free cash flow of $2.34B provides a financial cushion. The stock offers a 2.84% dividend yield, but a payout ratio of 149% indicates it is not currently sustainable from earnings.
Risks & Conditions: The two biggest risks are 1) a failure to restore net margins above 10%, and 2) a compression of the forward PE multiple if growth stalls. This Hold rating would upgrade to Buy if the company demonstrates two consecutive quarters of net margin expansion above 8% while maintaining revenue growth, signaling the turnaround is taking hold. It would downgrade to Sell if quarterly revenue growth turns negative or if the forward PE expands above 40x without corresponding margin improvement. Currently, the stock is overvalued relative to its current earnings power and financial health, but may be fairly valued if the ambitious turnaround succeeds as planned.
Sign up to view all
SBUX 12-Month Price Forecast
The 12-month outlook for SBUX is a binary bet on execution. The base case, with a 50% probability, sees the stock muddling through as the turnaround proves slower and more costly than hoped, leading to range-bound trading. The bull case requires a swift and dramatic margin recovery that seems optimistic given recent data. The bear case, driven by multiple compression on failed execution, presents a clear -21% downside risk. The stance is neutral because the compelling long-term brand strength and cash flow are fully offset by near-term financial deterioration and a premium valuation. The stance would turn bullish on evidence of sustained margin expansion; it would turn bearish on a breakdown below key technical support at $92.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Starbucks's 12-month outlook, with a consensus price target around $124.16 and implied upside of +30.0% versus the current price.
Average Target
$124.16
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$76 - $124
Analyst target range
The stock is covered by 11 analysts, providing a solid base of institutional research. The consensus sentiment appears mixed but leans cautiously optimistic, with recent actions including a downgrade from RBC Capital to 'Sector Perform' alongside maintained 'Buy' or 'Overweight' ratings from firms like BTIG, Barclays, and Piper Sandler. The average target price is not explicitly provided in the data, so the implied upside/downside cannot be calculated. The target price range is also not specified in the provided analyst data. The wide dispersion in recent analyst actions—from downgrades to reiterated bullish calls—signals high uncertainty and debate surrounding the pace and success of the company's turnaround strategy. This lack of clear consensus and a potentially wide target range would indicate that the stock's near-term path is highly dependent on the company's ability to deliver consistent quarterly execution against its strategic goals.
Bulls vs Bears: SBUX Investment Factors
The investment debate for SBUX centers on the high-conviction bet on a corporate turnaround versus the stark reality of severe financial strain and a premium valuation. Bullish evidence is rooted in early operational momentum, strong cash flow, and growth expectations priced into a lower forward PE. Bearish evidence is more concrete and present, anchored in collapsing quarterly profitability, a leveraged balance sheet, and a stock price trading near 52-week highs. Currently, the bear side holds stronger evidence due to the objective, severe deterioration in key financial metrics (net margin, ROE) which the bullish narrative must overcome. The single most important tension is whether CEO Brian Niccol's turnaround can restore sustainable double-digit net margins before valuation multiples contract from their elevated levels, eroding shareholder value.
Bullish
- Strong Turnaround Momentum: Recent news highlights the turnaround under CEO Brian Niccol is gaining steam, with a strong earnings beat and raised full-year outlook in April 2026. The stock's 17.98% one-year price change and 18.09% YTD gain reflect market optimism on this operational recovery.
- Robust Free Cash Flow Generation: The company generates substantial internal liquidity, with trailing twelve-month free cash flow of $2.34 billion. This provides a solid foundation to fund its strategic turnaround, maintain its 2.84% dividend yield, and navigate near-term profitability pressures.
- Positive Revenue Growth Trajectory: Revenue has grown from $8.56B in Q2 FY2024 to $9.91B in Q1 FY2026, with the latest quarter showing 5.43% YoY growth. Analyst consensus forecasts revenue to reach $47.35B, indicating expectations for continued top-line expansion.
- Forward PE Implies Earnings Recovery: The forward PE of 32.74x is significantly lower than the trailing PE of 52.58x, signaling the market expects a meaningful recovery in earnings. This is supported by analyst consensus EPS estimates of $5.08 for the forward period.
Bearish
- Severe Profitability and Margin Compression: Q1 FY2026 net income plummeted to $293M with a net margin of 2.96%, a drastic fall from 10.02% in Q4 FY2024. The quarterly gross margin of 15.63% is far below the TTM gross margin of 24.15%, indicating acute cost pressures.
- Extremely High and Strained Valuation: The trailing PE of 52.58x is exceptionally high for a mature consumer cyclical company and sits at the upper end of its own historical range. This leaves the stock vulnerable to multiple compression if the earnings recovery falters.
- Weak Balance Sheet and Negative ROE: The balance sheet shows significant strain with a negative Return on Equity (ROE) of -22.93% and a debt-to-equity ratio of -3.29. A current ratio of 0.72 indicates potential liquidity constraints in covering short-term obligations.
- Technical Overextension and Momentum Divergence: Trading at 91% of its 52-week high ($108.88), the stock is near the top of its range, suggesting limited near-term upside. A -6.01% 1-month price change and -12.32% relative strength vs. the S&P 500 signal recent momentum has broken down.
SBUX Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 17.98% one-year price change. As of the latest close at $99.16, the price is trading at approximately 91% of its 52-week high of $108.88, positioning it near the upper bounds of its annual range, which suggests strong momentum but also raises questions about potential overextension. The stock has experienced a notable short-term pullback, with a -6.01% decline over the past month and a modest 1.16% gain over three months, indicating recent momentum has decelerated and diverged negatively from the longer-term uptrend. This divergence, coupled with a negative 1-month relative strength of -12.32 versus the S&P 500, signals a period of consolidation or profit-taking after the strong run-up earlier in the year. Key technical levels are clearly defined by the 52-week high of $108.88 as immediate resistance and the 52-week low of $77.99 as major support. A breakout above resistance would confirm the resumption of the primary bull trend, while a breakdown below support would signal a more profound trend reversal. With a beta of 1.009, the stock exhibits market-average volatility, implying its price movements are generally in line with broader market swings, which is relevant for risk-adjusted portfolio positioning.
Beta
1.01
1.01x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$78-$109
Price range past year
Annual Return
+12.1%
Cumulative gain past year
| Period | SBUX Return | S&P 500 |
|---|---|---|
| 1m | -9.8% | +5.4% |
| 3m | -1.7% | +10.9% |
| 6m | +12.4% | +11.0% |
| 1y | +12.1% | +28.1% |
| ytd | +13.7% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SBUX Fundamental Analysis
Revenue growth has been positive but shows signs of deceleration and volatility on a quarterly basis. The most recent Q1 FY2026 revenue was $9.91 billion, representing a 5.43% year-over-year increase; however, this follows a sharper sequential decline from the prior quarter's $9.57 billion. Examining the trend, revenue has grown from $8.56 billion in Q2 FY2024 to the recent $9.91 billion, but quarterly sequential patterns have been inconsistent, indicating a business in transition rather than exhibiting smooth, accelerating growth. Profitability remains a critical concern, with net income for the latest quarter at $293 million, translating to a net margin of 2.96%, a significant compression from the 10.02% net margin reported in Q4 FY2024. The gross margin of 15.63% in Q1 FY2026 is notably lower than the trailing twelve-month gross margin of 24.15% reported in the valuation data, highlighting severe quarterly margin pressure, likely from input cost inflation and strategic investments. The balance sheet shows financial strain, with a negative Return on Equity (ROE) of -22.93% and a highly leveraged structure indicated by a debt-to-equity ratio of -3.29. Positively, the company generates substantial operating cash flow, with free cash flow over the trailing twelve months at $2.34 billion, providing internal funding for dividends and its turnaround efforts, though the current ratio of 0.72 suggests potential liquidity constraints in covering short-term obligations.
Quarterly Revenue
$9.9B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.15%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SBUX Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 52.58x, while the forward PE is lower at 32.74x, indicating the market is pricing in a significant recovery in earnings over the next twelve months. Compared to sector averages (data not available in the provided set), a precise premium/discount cannot be quantified, but a trailing PE above 50x is generally considered high for a mature consumer cyclical company, suggesting the market is paying for expected future improvement rather than current profitability. Historically, the stock's own valuation has been volatile; the current trailing PE of 52.58x is above the recent historical range seen in the data (e.g., 20.71x in Q3 FY2024, 83.00x in Q1 FY2026), placing it at the higher end of its own spectrum. This positioning near historical highs implies that investor expectations for a successful turnaround and margin recovery are already substantially baked into the current share price, leaving little room for execution missteps.
PE
52.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~184x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Starbucks faces acute profitability risks, with Q1 FY2026 net margin compressing to 2.96% from 10.02% just two quarters prior, driven by a quarterly gross margin of 15.63% versus a TTM average of 24.15%. The balance sheet is highly leveraged, evidenced by a negative ROE of -22.93% and a debt-to-equity ratio of -3.29, indicating significant financial strain. Furthermore, a current ratio of 0.72 suggests potential difficulty meeting short-term liabilities, and the company's revenue is heavily concentrated, with 74% derived from North America, exposing it to regional economic downturns.
Market & Competitive Risks: The primary market risk is extreme valuation compression. With a trailing PE of 52.58x—positioned at the high end of its own volatile historical range—the stock is priced for a perfect earnings recovery. Any stumble in the turnaround could trigger a severe derating. Competitive risks are heightened by the company's need to invest heavily in store experience and digital capabilities while managing costs, in a sector with intense rivalry for consumer disposable income. The stock's beta of 1.009 implies it will move with the market, so a broader sell-off in growth or consumer cyclical stocks would directly pressure SBUX.
Worst-Case Scenario: The worst-case scenario involves the turnaround failing to gain traction, leading to consecutive quarters of margin disappointment and slowing comparable sales growth. This would trigger analyst downgrades, a loss of investor confidence in the strategic plan, and a rapid compression of the PE multiple towards its 52-week low valuation. The realistic downside would be a retest of the 52-week low of $77.99, representing a potential loss of approximately -21% from the current price of $99.16. A drawdown of this magnitude is plausible, given the stock has already experienced a max drawdown of -19.06% during the provided period.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The collapse in quarterly net margin to 2.96% may persist or worsen due to inflation and investment costs. 2) Valuation Risk: The high trailing PE of 52.58x makes the stock vulnerable to severe multiple compression if growth stalls. 3) Balance Sheet Risk: Negative ROE (-22.93%) and a debt-to-equity ratio of -3.29 signal financial strain and limited flexibility. 4) Execution Risk: The entire investment thesis hinges on a successful multi-quarter turnaround with no room for error, as evidenced by mixed analyst sentiment and recent corporate layoffs.
The 12-month forecast is highly bifurcated, with three distinct scenarios. The base case (50% probability) sees the stock trading between $100 and $110 as the company shows slow, uneven progress on its turnaround. The bull case (25% probability) could drive the stock to $115-$125 on flawless execution and margin recovery. The bear case (25% probability) risks a decline to $78-$90 if the turnaround falters, triggering multiple compression. The base case is most likely, predicated on the assumption that the company's strong brand and cash flow will prevent a collapse, but operational headwinds will prevent a rapid re-rating higher in the near term.
SBUX is overvalued based on current fundamentals but may be fairly valued if its turnaround succeeds. The trailing PE of 52.58x is extremely high for a company with negative ROE and single-digit net margins, indicating the market is paying a large premium for hoped-for future profits. The forward PE of 32.74x, based on analyst EPS estimates of $5.08, is more reasonable but still implies strong growth. Compared to its own history, the stock trades at the higher end of its valuation range. The valuation implies the market expects a swift and significant recovery in profitability; any deviation from that path will likely lead to a downward re-rating.
SBUX is a high-risk, situational buy, not a core portfolio holding. For investors with a high risk tolerance and conviction in CEO Brian Niccol's turnaround strategy, the current price offers a entry point with an analyst-implied earnings recovery (forward PE 32.74x). However, given the severe margin compression (Q1 net margin 2.96%), leveraged balance sheet (ROE -22.93%), and rich valuation (trailing PE 52.58x), it is not a good buy for conservative or income-focused investors. The most attractive buyer is one who believes the operational improvements will materialize faster and stronger than the skeptical market expects.
SBUX is unsuitable for short-term trading due to its market-average volatility (beta 1.009) and current dependence on binary earnings events related to its turnaround. It is a candidate for a long-term (3-5 year) investment only for investors who believe in the multi-year durability of the brand and the management team's ability to execute a sustained operational repair. The 2.84% dividend yield provides some income, but the unsustainable 149% payout ratio means it could be at risk if earnings do not recover. A minimum holding period of 12-18 months is suggested to see through at least several quarterly earnings reports and gauge the turnaround's true trajectory.
